Authors:
Address: Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia. ming.qiao@health.sa.gov.au
Journal:
Publication:
abstractA dengue vaccine effective against all four serotypes is urgently needed. However, safety and immunogenicity could be affected by prior exposure to flaviviruses. This open, controlled, phase IIa study was conducted in 35 healthy adults who had received monovalent, live attenuated Vero cell-derived dengue vaccine against dengue virus 1 (VDV1) or 2 (VDV2) or yellow fever (YF) vaccine 1 year before or who were flavivirus-naïve. All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days. Previous vaccination did not increase reactogenicity, laboratory abnormalities, or incidence of vaccine viremia, but it did increase the neutralizing antibody response to dengue virus that persisted at day 180. There was no increase in YF antibodies in participants previously immunized with YF vaccine. Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity.
Related ArticlesLive attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.Hum Vaccin. 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, et al. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7. Epub 2006 Mar 15.
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.J Virol. 2001
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, et al. J Virol. 2001 Aug; 75(16):7290-304.
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.Virology. 2002
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, et al. Virology. 2002 Jun 20; 298(1):146-59.
Review From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.Vaccine. 2011
Review From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. Vaccine. 2011 Sep 23; 29(42):7229-41. Epub 2011 Jul 13.
Review Dengue vaccine.J Med Assoc Thai. 2005
Review Dengue vaccine.
Simasathien S, Watanaveeradej V. J Med Assoc Thai. 2005 Nov; 88 Suppl 3:S363-77.
Role of microparticles in dengue virus infection and its impact on medical intervention strategies.Yale J Biol Med. 2012
Role of microparticles in dengue virus infection and its impact on medical intervention strategies.
Bargeron Clark K, Hsiao HM, Noisakran S, Tsai JJ, Perng GC. Yale J Biol Med. 2012 Mar; 85(1):3-18. Epub 2012 Mar 29.
To
top
•
Home
Show
map | Diseases | Vaccination
| Chronic disease | Medicine
| Pregnancy
| Heat & Sunburn | Cold | Security
| Useful tips | Faq
| News
TraveldoctorOnline 2001 •
Disclaimer • webmaster
